pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ACRSAclaris Therapeutics, Inc.

$ACRS
Wayne, PA, USupdated 2mo ago
SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 1: 1Phase 2: 2
1Phase 12Phase 2
Phase 2
bosakitug
Atopic Dermatitis (Atopic Eczema)
Phase 2
lepzacitinib
Atopic Dermatitis (Atopic Eczema)
Phase 1
BSI-502
Atopic Dermatitis (Atopic Eczema)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitisactive not recruitingn=110
  • phase2Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitiscompletedn=14
  • phase2ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)completedn=95
  • phase2Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritisterminatedn=47
  • phase2Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitiscompletedn=250
  • phase2ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)completedn=251
  • phase2Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitiscompletedn=50
  • phase2Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)terminatedn=1
more trials →

Insider activity

source: SEC Form 4
routine RSU / option mechanics (3)
  • Mar 1, 26tax coverBalthaser Kevin · Chief Financial Officer677 sh
  • Mar 1, 26option exerciseBalthaser Kevin · Chief Financial Officer2,375 sh
  • Mar 1, 26option exerciseBalthaser Kevin · Chief Financial Officer2,375 sh
🐶 Hiring Signal
No open roles indexed yet — view Aclaris Therapeutics, Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$ACRS
SEC CIK
0001557746
country
US
source
sec_tickers
top tags
Dermatology3Asthma1Pulmonology1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 15m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?